Prediction of response to bevacizumab
Source: NCBI BioProject (ID PRJNA121947)

0 0

Project name: Homo sapiens
Description: The patients who underwent surgery for primary lesions were examined. All patients had metastatic or recurrent CRC and received bevacizumab therapy as first line or second line treatment. Responders and nonresponders were determined based on RECIST and confirmed by CT or MRI. Gene-expression profiles of primary CRC were determined using Human Genome GeneChip arrays U133.Overall design: Colorectal cancer patients who had undergone surgical resection of colorectal cancer were studied. To identify molecular signatures to predict response to bevacizumab, gene expression profiles were compared between Reponder and Non-responder.
Data type: Transcriptome or Gene expression
Sample scope: Multiisolate
Relevance: Medical
Organization: Department of Surgical Oncology, University of Tokyo
Last updated: 2010-01-12